Patents by Inventor Gilmore O'Neill

Gilmore O'Neill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20220296633
    Abstract: Methods for treating muscular dystrophy by administering a pharmaceutical composition comprising about 80 to about 300 mg/kg of an antisense oligomer, or pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: June 18, 2020
    Publication date: September 22, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventor: Gilmore O'NEILL
  • NRF2 Screening Assays and Related Methods and Compositions
    Publication number: 20180263906
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicant: Biogen MA Inc.
    Inventors: Matvey E. Lukashev, Gilmore O'Neill
  • NRF2 Screening Assays and Related Methods and Compositions
    Publication number: 20150366803
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Application
    Filed: May 21, 2015
    Publication date: December 24, 2015
    Inventors: Matvey E. Lukashev, Gilmore O'Neill
  • Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content
    Publication number: 20140163100
    Abstract: Methods of treating multiple sclerosis in a subject, including: reducing the frequency of relapse, reducing the annualized relapse rate, reducing the risk of disability progression, reducing the number of new or newly enlarging T2 lesions, reducing the number of gadolinium lesions; and methods of preserving/increasing myelin content in a subject having multiple sclerosis; by daily administering a composition containing a fumarate, such as dimethyl fumarate or monomethyl fumarate, to the subject.
    Type: Application
    Filed: May 25, 2012
    Publication date: June 12, 2014
    Applicant: Biogen IDEC MA Inc.
    Inventors: Katherine Dawson, Gilmore O'Neill, Alfred Sandrock
  • Treatment for multiple sclerosis
    Patent number: 8399514
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Grant
    Filed: February 13, 2012
    Date of Patent: March 19, 2013
    Assignee: Biogen Idec MA Inc.
    Inventors: Matvey E. Lukashev, Gilmore O'Neill
  • Treatment for Multiple Sclerosis
    Publication number: 20120196931
    Abstract: Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 2, 2012
    Applicant: Biogen Idec MA Inc.
    Inventors: Matvey E. LUKASHEV, Gilmore O'Neill